320 W 10th Ave
Columbus, OH 43210
Phone: (614) 293-9869
Assistant Professor, Hematology
Preceptor: Internal Medicine Clinc- 4 hrs. 1/18/11Resident morning report preceptor- 1/12/11 & 11/17/10
|1997 - present||New York State Pharmacy: New York State Medical Board|
|2005 - present||American Board of Internal Medicine Certification: American Board of Internal Medicine|
|2005 - present||New York State Medicine: New York State Medical Board|
|2008 - present||Ohio Sate Medical License: State Medical Board of Ohio|
|2008 - present||Hematology: American Board of Internal Medicine|
|2009 - present||Medical Oncology: American Board of Internal Medicine|
|09/01/2008||Outpatient Clinic Serivce (James Cancer Hospital, Hematology)|
|11/01/2008||Hematology II/ Acute Leukemia Service (The James Cancer Hospital)|
|12/01/2008||Hematology II/ Acute Leukemia Service (The James Cancer Hospital)|
|02/01/2009||Hematology II/ Acute Leukemia Service (The James Cancer Hospital)|
|03/01/2009||Hematology II/ Acute Leukemia Service (The James Cancer Hospital)|
|05/01/2009||Hematology II/ Acute Leukemia Service (The James Cancer Hospital)|
|06/01/2009||Hematology II/ Acute Leukemia Service (The James Cancer Hospital)|
|09/01/2009||Hematology II/ Acute Leukemia Service (The James Cancer Hospital)|
|10/01/2009||Hematology II/ Acute Leukemia Service (The James Cancer Hospital)|
|03/01/2010||Hematology II/ Acute Leukemia Service (The James Cancer Hospital)|
|05/01/2010||Hematology II/ Acute Leukemia Service (The James Cancer Hospital)|
|09/01/2010||Hematology II/ Acute Leukemia Service (The James Cancer Hospital)|
|07/01/2011||Hematology II/Acute Leukemia Service (The James Cancer Hospital)|
|08/01/2011||Hematology II/Acute Leukemia Service (The James Cancer Hospital)|
|11/01/2011||Hematology II/Acute Leukemia Service (The James Cancer Hospital)|
|01/01/2012||Hematology II/Acute Leukemia Service (The James Cancer Hospital)|
|08/01/2012||Hematology II/Acute Leukemia Service (The James Cancer Hospital)|
|11/01/2012||Hematology II/Acute Leukemia Service (James Cancer Hospital)|
|1997||B.S., State University of New York College at Buffalo|
|2002||M.D., University of Rochester|
|1992 - 1997||Deans List.|
|1993||Phi Eta Sigma freshman Honor Society.|
|1993||Golden Key National Honor Society.|
|1996||Rho Chi Pharmaceutical Honor Society.|
|1997||Robert H. Ritz Award.|
|2007||American Society of Hematology Clinical Research Training Institute.|
|2009||K-12 Award. NIH/NCI.|
|2010||ASH-AMFDP Award. ASH.|
|2010||Certificate of Excellence. The Ohio State Medical Center.|
|2011||Med I/II Integrated Pathway Program faculty recognition award.|
Walker AR, Rothberg PG, Liesveld JL. "A case of JAK2 positive essential thrombocythemia 16.5 years after autologous marrow transplantation for AML.." Bone Marrow Transplantation. Vol. 39, (January 2007.): 725-726.
Walker AR, Kleiner A, Rich L, Conners C., Fisher R. I., Anolik J., Friedberg J. W.. "Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.." Cancer Invest.. Vol. 4, no. 26. (May 2008.): 431-433.
Walker AR, Komrokji R, Ifthikharuddin J, Messina P., Mulford D., Becker M., Friedberg J., Oliva J., Phillips G., Liesveld J. L., Abboud C.. "Phase I study of Cladribine, Cytarabine (Ara-C), Granylocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevac) in Relapsed/Refactory AML.." Leuk Res. Vol. 12, no. 32. (January 2008.): 1830-1836.
Blum W, Garzon R, Klisovic RB, Schwind S, Walker AR, Geyer S., Liu S., Havelange V., Becker H., Schaaf L., Mickle J., Devine H., Kefauver C., Devine S. M., Chan K. K., Heerema N. A., Bloomfield C. D., Grever M. R., Byrd J. C., Villalona-Calero M., Croce C. M., Marcucci G.. "Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine." Proc Natl Acad Sci USA. Vol. 16, no. 107. (April 2010.): 7473-7478.
Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A , et al.. "Dose escalation of lenalidomide in relapsed or refractory acute leukemias.." J Clin Oncol.. Vol. 28, (January 2010.): 4919-4925.
Walker A, Marcucci G.. "Prognostic factos in acute myeloid leukemia with normal karyotype." Haematologica. Vol. 96, no. 5. (January 2011.): 640-643.
KH Metzeler, Walker AR, S Geyer, R Garzon, RB Klisovic, CD Bloomfield, W Blum, and G Marcucci. "DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia." Leukemia. Vol. 26, (January 2011.): 1106-1107.
Walker,Alison; Marcucci,Guido. "Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse." HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. Vol. 96, no. 5. (May 2011.): 640-643.
Hickey C J., Schwind S, Radomska H S., Dorrance AM, Santhanam R, Mishra A, Wu Y, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A,. Eiring A M, Whitman S P, Becker H, Perrotti D, Wu L, Zhao X, Fehniger T A, Vij R, Byrd J C., Blum W, Lee L, Caligiuri M A, Bloomfield CD, Garzon R, Marcucci G. "Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein upregulates expression of the anti-leukemic microRNA-181a in acute myeloid leukemia.." Blood. Vol. 10.1182, (October 2012.): 2012-05.
Pearlly Yan, David Frankhouser, Mark Murphy, Hok-Hei Tam, Benjamin Rodriguez, John Curfman, Michael Trimarchi, Susan Geyer, Yue-Zhong Wu, Susan P. Whitman, Klaus Metzeler, Alison Walker, Rebecca Klisovic, Samson Jacob, Michael R. Grever, John C. Byrd, Clara D. Bloomfield, Ramiro Garzon, William Blum, Michael A. Caligiuri, Ralf Bundschuh, Guido Marcucci. "Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.." Blood. Vol. 120(12), (July 2012.): 2466-74.
Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, Lee LJ, Jacob S, Mrozek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G.. "Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia.." Leukemia. Vol. doi: 10.1038, (November 2012.): leu.2012.342-.
Racke F, Cole C, Walker AR, Jones J, Heerema NA. ". Therapy-related pro-B cell acute lymphoblastic leukemia: report of two patients with MLL amplification." Cancer Genetics. Vol. 0, (December 2012.): 0-.
Walker A, Marcucci G. "Molecular prognostic factors in cytogenetically normal acute myeloid leukemia.." Expert Rev Hematol.. Vol. 5(5), (October 2012.): 547-58.
Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci G. "In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia.." AAPS J. Vol. Doi: 10.1208/S12248-012-9427-5, (November 2012.): 1-8.
Tallman M, Chung S, Damon L, Marcucci G, Walker A, Madhava B. "75-year-old woman with Thoracic Spinal Cord Compression and Chloroma (Granulocytic Sarcoma).." Seminars in Oncology. Vol. 39, (December 2012.): e37-e46.
Blum,William; Schwind,Sebastian; Tarighat,Somayeh,S; Geyer,Susan; Eisfeld,Ann-Kathrin; Whitman,Susan; Walker,Alison; Klisovic,Rebecca; Byrd,John,C; Santhanam,Ramasamy; Wang,Hongyan; Curfman,John,P; Devine,Steven,M; Jacob,Samson; Garr,Celia; Kefauver,Cheryl; Perrotti,Danilo; Chan,Kenneth,K; Bloomfield,Clara,D; Caligiuri,Michael,A; Grever,Michael,R; Garzon,Ramiro; Marcucci,Guido. "Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia." BLOOD. Vol. 119, no. 25. (June 2012.): 6025-6031.
Ranganathan,Parvathi; Yu,Xueyan; Na,Caroline; Santhanam,Ramasamy; Shacham,Sharon; Kauffman,Michael; Walker,Alison; Klisovic,Rebecca; Blum,William; Caligiuri,Michael; Croce,Carlo,M; Marcucci,Guido; Garzon,Ramiro. "Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.." Blood. Vol. 120, no. 9. (August 2012.): 1765-1773.
Walker A, Marcucci G. "Introduction: Genetics and Classification of AML. Targeted Therapy of Acute Myeloid Leukemias.." In press. -.
|December 2006||Abbound, C, Walker AR, Komorokji, R. et al.."Phase I study of cladribine, cytarabine (Ara-C), Granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating does of imantinib mesylate (Gleevac) in relapsed/refactory AML." Washington D.C..|
|January 2009||Blum W, Klisovic R, Walker AR, et al.."Epigenetic targeting via transcriptional inhibition of DNA methyltransferase: a Phase 1 studay of Bortezomib in Comination with 5-azacytidine in Adults with relapsed or refactory Acute Myeloid Leukemia." New Orleans.|
|January 2009||Chen P, Blum W, Aimiuwu J, Upadhyayula V, Liu Z, Lui S, Pang J, Walker AR, et al.."Quantification of Intracelluar Decitabine-Triphosphate with A Novel, Highly Sensitive and Specfic LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine" New Orleans.|
|January 2009||Chandler J, Klisovic R, Phelps M, Walker AR et al.."Phase I Studay of Lenalidomide in Acute Myeloid Leukemia: Remissions Post-allogeneic relapse of Acute Myeloid Leukemia" New Orleans.|
|January 2010||Blum W, Klisovic B, Garzon R, Walker A , et al.."Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)." Orlando.|
|January 2010||Gojo I, Walker A , Cooper M, et al.."Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias." Orlando.|
|January 2011||Walker AR,Metzeler Klaus H, Geyer Susan, et al.."Impact of DNMT3A Mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)" San Diego.|
|April 2012||Alice S. Mims, Alison R. Walker, Hongyan Wang, Xiaomeng Huang, Ramasamy Santhanam, Pia Hoellerbauer, Somayeh Tarighat, Kenneth K. Chan, Rebecca B. Klisovic, Danilo Perrotti, Michael A. Caligiuri, John C. Byrd, Ching-Shih Chen, William Blum, Ramiro Garzon, Sebastian Schwind, Guido Marcucci."AR-42, a Histone Deacetylase Inhibitor, increases microRNA-29b and sensitizes cells to decitabine treatment: a novel epigenetic-targeting approach in Acute Myeloid Leukemia" Chicago.|
|April 2012||Schwind S, Blum W, Liu S, Tarighat S, Geyer S, Klisovic R, Eisfeld A, Walker A, Whitman S, Ramasamy S, Wu Y, Jacob S, Caligiuri M, Grever M, Perrotti D, Byrd J, Bloomfield C, Garzon R, Marcucci G."The Combination of Bortezomib (BOR) and Decitabine (DEC): a Phase I Trial in Patients (Pts) with Acute Myeloid Leukemia (AML) targeting FLT3 expression" Chicago.|
"MDS- myelodysplastic syndromes." Presented at ASH Review, Columbus, OH. (January 2009)
"MDS- myelodysplastic syndromes." Presented at ASH Review, Columbus, OH. (January 2010)
"Careers in Medicine." Presented at DIVE, Columbus, OH. (March 2010)
"MDS- myelodysplastic syndromes." Presented at Fellows Science and Clinical Lecture Series, Columbus, OH. (May 2010)
"APL - Acute Promyelocytic Leukemia." Presented at Fellows Science and Clinical Lecture Series, Columbus, OH. (November 2010)
"Impact of Mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients with Acute Myeloid Leukemia.." Presented at American Society of Hematology, San Diego, CA. (December 2011)
"Approach to the patient with cytopenias." Presented at 2011 Department of Internal Medicine Conference, Columbus, OH. (December 2011)
"Clinical Skills Center." Presented at Canady Conference for Future Doctors and Dentists, Columbus, OH. (April 2011)
"DNMT Mutations and Response to Decitabine." Presented at CALGB, Chicago, IL. (September 2011)
"Targeting the Expression of Mutated genes encoding Tyrosine Kinases in Acute Myeloid Leukemia." Presented at Harold Amos Medical Faculty Development Program, New Orleans, LA. (October 2011)
"Impact of DNMT3A Mutations in AML patients treated with Decitabine." Presented at CALGB, Chicago, IL. (November 2011)
|2009 - present||CDK Acute Leukemia Advisory Board. Schering-Plough. Short Hills, NJ.|
|2009 - present||Dicussing Myeloid Diseases. It's All About Health Radio Show.|
|2011 - present||Free Clinic. Columbus, OH.|
|2011 - present||ARNO Advisory Board Meeting. Arno Therapeutics. New York City, NY.|
|2011 - present||Community Day. OSU Medical Center. Columbus, OH.|
|2000 - 2002||Hospice.|
|- 2012||Health Seminar Speaker. Friendship Missionary Baptist Church. Columbus, OH.|
|- 2012||Myelodysplastic Syndrome Broadcast. WBNS/TV-10.|
|- 2012||The Black History Month Program.|
|- 2012||TKI vs. imatinib for first line treatment in CML. HemOnc Today Newspaper.|
|- 2012||MDS Awareness. WCMH/TV-4.|
|- 2012||Doctor Day Hotline.|